when were glp-1 agonists approved for weight loss Glucagon-like peptide-1 receptor: mechanisms and advances in therapy Comparative efficacy and safety of
Description
These therapies, initially designed for type 2 diabetes, have demonstrated significant weight loss benefits, leading to their expanded use in obesity management

Current Clinical Pharmacology

Design of antagonists for NMDA and AMPA receptors

Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: A systematic review and meta-analysis of cardio-vascular outcome trials

Peptide Hormone Exendin-4 Stimulates Subventricular Zone Neurogenesis in the Adult Rodent Brain and Induces Recovery in an Animal Model of Parkinsons Disease
Pregnancy or plans to become pregnant
